Acting as key components of peptide-MHC ligands for T cell receptors (TCR), either MHC-I restoration (Gu et al, 2021; Pulido et al, 2020) or epitope delivery-mediated forced antigenicity (Cuburu et al, 2022; Millar et al, 2020; Rosato et al, 2019) have been demonstrated to be effective in potentiating tumor immunotherapy. The gene discussed is HLA-C; the disease is neoplasm.